Adjuvanticity of Ganoderma lucidum polysaccharide liposomes on porcine circovirus type-II in mice

• Published in: International journal of biological macromolecules 2019-12, Vol.141, p.1158-1164
• Main Authors: Liu, Zhenguang, Zhu, Tianyu, He, Jin, Zhang, Yue, Gu, Pengfei, Qiu, Tianxin, Bo, Ruonan, Hu, Yuanliang, Liu, Jiaguo, Wang, Deyun
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - pharmacology; Animals; CD4-Positive T-Lymphocytes - cytology; CD4-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - cytology; CD8-Positive T-Lymphocytes - drug effects; Cell Count; Cell Proliferation - drug effects; Circovirus - immunology; Cytokines - blood; Female; Fungal Polysaccharides - pharmacology; Ganoderma - chemistry; Ganoderma lucidum polysaccharides; Immune response; Immunoglobulin G - immunology; Liposomes; Lymphocyte Activation - drug effects; Mice; Mice, Inbred BALB C; PCV-II; Spleen - immunology
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2019.09.079

[Display omitted] Ganoderma lucidum has been widely used as a fungal, for promoting health and longevity in China and other Asian countries. Polysaccharide (PS) extracted from Ganoderma lucidum exhibits a variety of immunomodulatory activities and has the ability to induce strong immune responses. Liposomes (Lip) have been shown to be useful carriers of vaccine antigens and can be applied as a versatile delivery system for vaccine adjuvants. Here, PS and inactivated porcine circovirus type II (PCV-II) were encapsulated into Lip as a vaccine and inoculated into mice. The magnitude and kinetics of adjuvant activity were investigated. Polysaccharide-loaded liposomes (Lip-PS) could induce more efficient PCV-II-specific immune responses than other single-component formulations. The Lip-PS group displayed robust and higher titers of PCV-II-specific immunoglobulin (Ig)G antibodies and IgG subtypes as well as higher cytokine levels, furthermore, splenocytes were activated by Lip-PS. Thus, Lip-PS formulation produced vigorous humoral and cellular immune responses, with a mixed T-helper (Th)1/Th2/Th17 immune response and slight Th1 polarized cellular immune response. Overall, these results suggested that Lip-PS could provide a universal platform for vaccine design against PCV-II.